FCCC LOGO Faculty Publications
Hoffman JP , Lipsitz S , Pisansky T , Weese JL , Solin L , Benson AB
Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: An eastern cooperative oncology group study
Journal of Clinical Oncology. 1998 Jan;16(1) :317-323
PMID: ISI:000071368500046   
Back to previous list
Purpose: A prospective, multiinstitutional trial was initiated in 1991 to examine the tolerance to and efficacy of a program of preoperative chemorcadiotherapy (CTRT) and surgical resection for patients with localized adenocarcinoma of the pancreas. Patients and Methods: Fifty-three patients were assessable for analysis, with a median follow-up of 52 months for survivors. Radiation therapy (RT) totaling 5,040 cGy in 180 cGy fractions with mitomycin 10 mg/m(2) day 2 and fluorouracil (5-FU) 1,000 mg/m(2)/d continuous infusion days 2 through 5 and 29 through 32 were given as preoperative adjuvant therapy Twelve patients did not proceed to surgery (one death, one toxicity, three local progression, six distant metastases, one intercurrent illness), whereas 41 patients underwent surgery. Of these, 17 patients did not have resection (11, hepatic and/or peritoneal metastases and six local extension that precluded resection). Twenty-four patients had tumor resection (19 Whipple, four total pancreatectomy, one distal pancreatectomy). Results: Treatment toxicity was primarily hematologic, although a comparable number suffered biliary tract complications, either from obstruction or cholangitis as a result of an occluded stent or the primary tumor. there was one postoperative death. Median survival for the entire group and for the 24 patients with resection was 9.7 and 15.7 months. This survival rate reflected the advanced state of most resected cancers (positive peritoneal cytology, three patients; margins within 2 mm, 13 patients; involved lymph nodes, four patients; and need for superior mesenteric vein (SMV) resection, four patients). tumor progression was most frequent at metastatic sites. Conclusion: This preoperative CTRT protocol was feasible and safe in a cooperative group setting. Entry of patients with advanced tumors probably accounted for the suboptimal resectability and survival results. (C) 1998 by American Society of Clinical Oncology.
Times Cited: 59 English Article YQ270 J CLIN ONCOL